Mechanisms of Adstiladrin Sensitivity and Resistance in Bladder Cancer

Abstract

Intravesical interferon gene therapy is being developed by our lab as an alternative treatment for patients with BCG-unresponsive bladder cancer. With the clinical samples (tissue and urine) from the phase 3 clinical trial, we proposed to perform deep genomic sequencing and metabolomic analyses to identify novel predictive biomarkers that will be used to develop novel combination studies to overcome resistance. At this study site (MD Anderson Cancer Center), we will also use preclinical models to complement our clinical studies by a) characterizing the effects of Ad-IFN on tumor microenvironment and b) define the role of fatty acid metabolism in Ad-IFN induced cell death.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Aug 01, 2023
Accession Number
AD1215415

Entities

People

  • Colin P. Dinney

Organizations

  • The University of Texas MD Anderson Cancer Center

Tags

DTIC Thesaurus Topics

  • Abstracts
  • Biological Factors
  • Biomedical Research
  • Bladder Cancer
  • Cancer
  • Cell Line
  • Chemistry
  • Clinical Trials
  • Data Analysis
  • Fatty Acids
  • Gene Therapy
  • Interferon
  • Neoplasms
  • Professional Development
  • Proteins
  • Resistance
  • Therapy

Fields of Study

  • Medicine

Readers

  • Gulf War Illness and Chronic Multisymptom Illness in Veterans.
  • Oncology (Cancer Research).
  • Prostate Cancer Biology.

Technology Areas

  • Biotechnology
  • Biotechnology - Cancer Biotech